What is B. Riley's Estimate for TG Therapeutics Q3 Earnings?

Key Points

• B. Riley has revised its Q3 2025 earnings per share estimate for TG Therapeutics down from $0.27 to $0.25, while maintaining a "Buy" rating and a price target of $55.00.
• The consensus estimate for TG Therapeutics full-year earnings is significantly lower, at just $0.08 per share, indicating cautious expectations for the company's performance.
• The company is experiencing volatility, with its stock currently trading around $32.04, and has a market capitalization of $5.08 billion.

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Research analysts at B. Riley lowered their Q3 2025 earnings per share (EPS) estimates for TG Therapeutics in a research report issued to clients and investors on Wednesday, September 17th. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutical company will earn $0.25 per share for the quarter, down from their prior forecast of $0.27. B. Riley currently has a "Buy" rating and a $55.00 price objective on the stock. The consensus estimate for TG Therapeutics' current full-year earnings is $0.08 per share. B. Riley also issued estimates for TG Therapeutics' FY2025 earnings at $0.84 EPS and FY2027 earnings at $2.13 EPS.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The firm had revenue of $141.15 million for the quarter, compared to analyst estimates of $147.76 million. During the same period in the previous year, the company earned $0.04 EPS. TG Therapeutics's revenue was up 92.1% compared to the same quarter last year. TG Therapeutics has set its FY 2025 guidance at EPS.

Separately, The Goldman Sachs Group raised TG Therapeutics to a "hold" rating and set a $37.00 target price for the company in a report on Thursday, July 10th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $48.00.

TG Therapeutics Price Performance

Shares of TG Therapeutics stock traded up $2.60 during mid-day trading on Thursday, reaching $34.97. 3,447,463 shares of the stock traded hands, compared to its average volume of 2,056,701. The business has a 50-day moving average of $31.84 and a 200 day moving average of $35.63. TG Therapeutics has a fifty-two week low of $21.16 and a fifty-two week high of $46.48. The stock has a market capitalization of $5.55 billion, a PE ratio of 94.51 and a beta of 1.88. The company has a quick ratio of 2.96, a current ratio of 3.86 and a debt-to-equity ratio of 0.89.

Insider Activity at TG Therapeutics

In other news, Director Sagar Lonial sold 20,852 shares of the firm's stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total transaction of $672,268.48. Following the completion of the transaction, the director directly owned 94,061 shares in the company, valued at $3,032,526.64. This trade represents a 18.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 10.64% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Thrivent Financial for Lutherans boosted its position in shares of TG Therapeutics by 1.7% during the second quarter. Thrivent Financial for Lutherans now owns 99,715 shares of the biopharmaceutical company's stock worth $3,589,000 after buying an additional 1,677 shares during the period. Marex Group plc purchased a new position in shares of TG Therapeutics during the second quarter worth $10,017,000. Advisory Services Network LLC boosted its position in shares of TG Therapeutics by 66.3% during the second quarter. Advisory Services Network LLC now owns 20,205 shares of the biopharmaceutical company's stock worth $717,000 after buying an additional 8,054 shares during the period. Hohimer Wealth Management LLC purchased a new position in shares of TG Therapeutics during the second quarter worth $308,000. Finally, Geneos Wealth Management Inc. boosted its position in shares of TG Therapeutics by 200.0% during the second quarter. Geneos Wealth Management Inc. now owns 2,169 shares of the biopharmaceutical company's stock worth $78,000 after buying an additional 1,446 shares during the period. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.